Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Nxera Pharma UK Limited
Nxera Pharma UK Limited
Industry · 14 registered clinical trials.
Status
Trial
Phase
Started
Completed
Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution
Healthy Subjects
Phase 1
2021-07-29
Terminated
A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562
Healthy
Phase 1
2021-05-25
Completed
Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects
Healthy
Phase 1
2020-06-29
Withdrawn
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
Dementia With Lewy Bodies
Phase 2
2019-07-01
Completed
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
Healthy
Phase 1
2019-01-23
Completed
Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242
Healthy
Phase 1
2018-11-14
Completed
Measurement of HTL0016878 in Cerebrospinal Fluid
Healthy Subjects
Phase 1
2018-09-26
Completed
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
Alzheimer's Disease
Phase 1
2017-11-10
Completed
A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878
Healthy
Phase 1
2017-08-25
Completed
Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects
Safety Issues, Pharmacokinetics
Phase 1
2017-05-16
Completed
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
Bioavailability and Pharmacokinetics
Phase 1
2016-10-01
Completed
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Do
Alzheimer's Disease
Phase 1
2016-02-01
Completed
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjec
Alzheimer's Disease
Phase 1
2015-10-01
Completed
Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive I
Alzheimer's Disease
Phase 1
2013-11-01